Early approvals for new treatments, such as those for COVID-19, could get delayed by the standards the FDA used for older drugs, according to a new study
The protein structure facilitates viral entry into host cells making it a key target for vaccine and antiviral drug development, according to the researchers
500,000 patient specimens are being collected and tested as an initiative is underway to identify asymptomatic patients while also protecting high-risk population